43rd Annual Meeting 
of the European Society for 

Blood and Marrow Transplantation
26-29 March 2017 • Marseille, France
SIGN UP FOR UPDATES
REGISTER NOW
  • Home

  • Meeting Information

  • Abstracts

  • Program

  • Registration & Accommodation

  • Media

  • Support & Exhibition

  • More

    Copyright © 2016 EBMT2017.org. All Rights Reserved
    Meeting Organizers
    CME Congresses
    P: +972 3 555 0188
    F: +972 3 540 1566
    ebmt@cme-congresses.com
    Venue 
    Palais des Congrès - Marseille Chanot 
    Parc Chanot, Rond-Point du Prado, 13009 Marseille, France 
    www.marseille-chanot.com
    Contact Information
    Abstracts
    ebmt.abstracts@cme-congresses.com

    Registration & Accommodation 
    ebmt.reg@cme-congresses.com
    Membership
    membership@ebmt.org

    Educational Sessions

     

    Monday, March 27th

    09:00-10:30 - Morgiou

    E1: Transplant in non-hematological disorders

    Chairs:                  John Snowden, UK & Francesco Lanza, Italy

    09:00-09:30         HSCT for multiple sclerosis and other autoimmune diseases of the nervous system: Harold Atkins, Canada

    09:30-10:00         High-dose chemotherapy and autologous stem cell transplantation in breast cancer: a never ending story?
                                  Antony Goncalves, France

    10:00-10:30         Stem cell therapy in Rheumatic diseases: Dominique Farge-Bancel, France

     

    11:00-12:30 - Auditorium

    E2: Transplant in myeloma

    Chairs:                  Mohamad Mohty, France & William Bensinger, USA

    11:00-11:30         The role of upfront auto transplantation in myeloma: William Bensinger, USA

    11:30-12:00         Double autotransplant: Jean-Luc Harousseau, France

    12:00-12:30         Autotransplantation in elderly patients with multiple myeloma: Joan Bladé, Spain

     

    11:00-12:30 - Amphithéâtre Callelongue

    E3: Allogeneic transplantation and gene therapy of inherited disorders

    Chairs:                  Isabelle Thuret, France & Simone Cesaro, Italy

    11:00-11:30         Primary Immunodeficiencies: Andrew Gennery, UK

    11:30-12:00         Fanconi anemia and other inherited marrow failure disorders: Carlo Dufour, Italy

    12:00-12:30         SCID: Marina Cavazzana, France

     

    14:30-16:00 - Auditorium

    E4: Transplant in the treatment algorithm of myeloid disorders

    Chairs:                  Norbert Vey, France & Jorge Sierra, Spain

    14:30-15:00         Transplant in the treatment algorithm of AML: Jorge Sierra, Spain

    15:00-15:30         MDS: Uwe Platzbecker, Germany

    15:30-16:00         MPN: Nicolaus Kröger, Germany

     

    14:30-16:00 - Les Goudes 1

    E5: Transplant in the treatment algorithm of lymphoma

    Chairs:                  Noël Milpied, France & Silvia Montoto, UK

    14:30-15:00         Hematopoietic cell transplantation for T-cell lymphomas: when is the right time to offer it?
                                  Mohamed Kharfan-Dabaja, USA

    15:00-15:30         Mantle cell lymphoma: Steve LeGouill, France

    15:30-16:00         Rare lymphomas: Peter Dreger, Germany

     

    Tuesday, March 28th

    09:00-10:30 - Hall 2

    E6: Management of rare early post-transplant complications

    Chair:                   Rafael Duarte, Spain

    09:00-09:30         Neurological disorders: Rémy Duléry, France, France

    09:30-10:00         TMA: Paul Coppo, France

    10:00-10:30         Capillary leak syndrome: Enric Carreras, Spain

     

    09:00-10:30 - Auditorium

    E7: GVHD

    Chairs:                  Pierre-Simon Rohrlich, France & Sophie Paczesny, USA

    09:00-09:30         Current issues in the management of acute GVHD: Gerard Socié, France

    09:30-10:00         Therapy of chronic GVHD: Dawn of targeted intervention: Madan Jagasia, USA

    10:00-10:30         Biomarkers to guide GVHD prevention and preemptive therapy: Jan Storek, Canada

                   

    11:00-12:30 - Hall 2

    E8: Post-transplant therapies for relapse prevention

    Chairs:                  Ibrahim Yakoub-Agha, France & Arnon Nagler, Israel

    11:00-11:30         Prophylactic and pre-emptive DLI: Christoph Schmid, Germany

    11:30-12:00         FLT3-inhibitors - prior and post-transplant: Richard Schlenk, Germany

    12:00-12:30         Hypomethylating agents: Charles Craddock, UK

     

    11:00-12:30 - Les Goudes 1

    E9: Some transplant challenges across the world

    Chairs:                  Mahmoud Al-Jurf, Saudi Arabia & Dietger Niederwiesser, Germany

    11:00-11:30         HSCT challenges in the Eastern-Mediterranean and Middle-East region: Amir Ali Hamidieh, Iran

    11:30-12:00         Setting up a new transplantation program: Mickey Koh, UK/Singapore

    12:00-12:30         Emerging infectious threats: Zika virus, Chikungunya, Dengue etc: Jan Styczynski, Poland

     

    Wednesday, March 29th

    09:00-10:30 - Les Goudes 2

    E10: Late post-transplant complications

    Chairs:                  Bipin Savani, USA & Rafael Duarte, Spain

    09:00-09:30         Metabolic syndrome in adults transplanted during childhood: Gérard Michel, France

    09:30-10:00         Revaccination post-transplant: Eolia Brissot, France

    10:00-10:30         Physical Symptoms: Bipin Savani, USA

     

    09:00-10:30 - Endoume 3

    E11: Criteria for donor choice: HLA & beyond

    Chairs:                  Christophe Picard, France & Alejandro Madrigal, UK

    09:00-09:30         NGS in HLA-typing: are all mismatches equivalent? Jean Marie Tiercy, Switzerland

    09:30-10:00         Permissive mismatches: Katharina Fleischhauer, Germany

    10:00-10:30         The non-conventional MHC-I and MICA gene is critically involved in GVHD: Seiamak Bahram, France

                      

    11:00-12:30 - Les Goudes 2

    E12: Pre and post-transplant interventions

    Chairs:                  Olivier Hermine, France & Hans-Jochem Kolb, Germany

    11:00-11:30         Novel antibodies: Ali Bazarbachi, Lebanon

    11:30-12:00         Immune checkpoint inhibitors: Ali Bazarbachi, Lebanon

    12:00-12:30         Anti-complement drug and allogeneic HSCT: Régis Peffault de Latour, France